Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094243 | 0.85 | SLC6A3 (0.59) | MAPTPKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4754551 | 0.82 | GPR119 (0.44) | ALDH1A1MAPTPKMKDM4E | |
| SCHEMBL6082005 | 0.78 | TSHR (0.49) | ALDH1A1SMN1; SMN2MAPTPKMHTT | |
| SCHEMBL4757346 | 0.78 | MAPT (0.46) | ALDH1A1MAPTPKMSLC6A2SLC6A4 | |
| SCHEMBL6829116 | 0.77 | SLC6A3 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10839544 | 0.77 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4757240 | 0.77 | CHRM2 (0.45) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2508884 | 0.76 | MAPT (0.47) | ALDH1A1SMN1; SMN2MAPTPKMHTT | |
| SCHEMBL1896746 | 0.76 | USP30 (0.51) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL21865774 | 0.75 | MAPT (0.41) | ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | ALDH1A1 3412/4885SMN1; SMN2 4526/4885MAPT 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.